.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical consequence of 11 months, individuals along with metastatic stomach cysts that acquired biomarker-matched treatments based upon distributing cyst DNA profiling revealed a more significant professional perk than those receiving incomparable therapy.